Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083
Mark A. Marzinke(Family Health International 360), Susan H. Eshleman(Johns Hopkins University), Adeola Adeyeye(National Institutes of Health), Myron S. Cohen(University of North Carolina at Chapel Hill), Beatriz Grinsztejn(Fundação Oswaldo Cruz), Deborah Persaud(Johns Hopkins University), Estelle Piwowar‐Manning(Johns Hopkins University), Marty St. Clair(Coe College), Maoji Li(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Keren Middelkoop(Desmond Tutu HIV Foundation), Christos J. Petropoulos(IGM Biosciences (United States)), Raphael J. Landovitz(APLA Health), Marybeth McCauley(Family Health International 360), James F. Rooney(Gilead Sciences (United States)), Aditya H. Gaur(St. Jude Children's Research Hospital), Casey D Haines(Johns Hopkins University), Nittaya Phanuphak(HIV Netherlands Australia Thailand Research Collaboration), Craig W. Hendrix(Unknown), Peter L. Anderson(University of Colorado Denver), Deborah Donnell(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Shahnaz Ahmed(Johns Hopkins University), Lara E. Coelho(UCLA Medical Center), Ryan Kofron(APLA Health), Lane R. Bushman(University of Colorado Anschutz Medical Campus), Brett Hanscom(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Vanessa Cummings(Johns Hopkins University), Alex R. Rinehart, Daniel Pryluka, Lei Weng(Fred Hutch Cancer Center), Jessica M. Fogel(Johns Hopkins University)
Cited by 129
Related Papers
Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women
|New England Journal of Medicine|2012|3.3k
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
|New England Journal of Medicine|2021|2.6k
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection
|New England Journal of Medicine|2015|1.6k
Rapid evolution of the neutralizing antibody response to HIV type 1 infection
|Proceedings of the National Academy of Sciences|2003|1.2k
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
|New England Journal of Medicine|2021|847